When you are pregnant, the thought of your unborn child’s neurological development is never far from your mind. You take your folic acid supplements, follow your doctor’s advice, and attend every antenatal appointment. But there is one important test that many Indian doctors are now beginning to recommend — the FRAT test during pregnancy — that most expectant mothers have never heard of.
This guide explains what the FRAT test is, why it matters specifically during pregnancy, how a mother’s immune status can affect her developing baby’s brain, and what Indian medical guidelines and specialist opinions currently recommend.
What Is the FRAT Test and Why Does It Matter in Pregnancy?
The FRAT test (Folate Receptor Antibody Test) detects the presence of Folate Receptor Autoantibodies (FRAAs) in the blood — immune proteins that mistakenly attack the Folate Receptor Alpha (FRα) protein. This receptor is essential for transporting folate (Vitamin B9) across biological barriers, including the blood-brain barrier in the foetus.
During pregnancy, folate is not just important for preventing neural tube defects — it is critical throughout the entire nine months for foetal brain development, cell division, and the formation of the nervous system. If a pregnant woman is producing FRAAs, these antibodies can:
- Interfere with placental folate transport, limiting the supply of folate reaching the foetus
- Cross the placenta themselves, directly affecting the developing foetal brain’s ability to uptake folate
- Potentially be passed through breast milk postnatally, continuing to affect folate transport in the infant’s developing brain
This mechanism is why researchers and clinicians now believe that maternal FRAT status — not just dietary folate intake — may play a significant role in determining a child’s risk of neurodevelopmental disorders including autism spectrum disorder (ASD) and Cerebral Folate Deficiency (CFD).
The Research Evidence: Maternal FRAAs and Foetal Brain Development
The scientific basis for FRAT testing during pregnancy comes from multiple lines of evidence. Research published in peer-reviewed journals has demonstrated the following:
Maternal FRAAs Cross the Placenta
Studies have confirmed that IgG class Folate Receptor Autoantibodies — which are typically the blocking type — can cross the placental barrier and enter foetal circulation. This is not unique to FRAAs; other maternal autoantibodies, such as those associated with neonatal lupus and some cases of congenital heart block, also cross the placenta and affect the foetus. The implication is that a mother who is FRAT-positive during pregnancy is not just affected herself — she may be directly transmitting the antibodies to her unborn child.
Association with Neurodevelopmental Risk
A study published in the journal Frontiers in Psychiatry found that mothers of children with ASD had significantly higher rates of FRAA positivity compared to control mothers. This suggests that maternal FRAA status may be an independent risk factor for neurodevelopmental disorders in offspring. Multiple PubMed-indexed studies support this association.
Placental Folate Transport Impairment
FRα is highly expressed in the placenta, where it plays a central role in concentrating and transporting folate to the developing foetus. When maternal FRAAs are present, they can bind to placental FRα and impair this function, even when maternal serum folate levels appear entirely normal. Standard dietary folic acid supplementation, while important for neural tube defect prevention, cannot compensate for impaired receptor-mediated transport in the same way that folinic acid can.
Why Standard Folic Acid Supplements Are Not Enough for FRAT-Positive Mothers
This is one of the most important distinctions that Indian expectant mothers need to understand. The standard antenatal advice — take 400–800 mcg of folic acid daily — is designed to prevent neural tube defects and support general foetal health. It is excellent advice for the general population.
However, regular folic acid relies primarily on the Folate Receptor Alpha pathway to be transported across cellular barriers, including into the placenta and through the blood-brain barrier. If FRAAs are blocking this receptor, simply increasing folic acid dosage may not be sufficient to overcome the transport deficiency.
Folinic acid (leucovorin), on the other hand, uses alternative transport mechanisms that bypass the blocked FRα receptor. For FRAT-positive pregnant women, supplementation with folinic acid — under medical supervision — may be a more effective intervention than standard folic acid alone. This distinction underlines why identifying FRAA status during pregnancy matters so much for clinical management.
Who Should Consider FRAT Testing During Pregnancy?
Not every pregnant woman requires FRAT testing. However, the following circumstances significantly increase its clinical value:
Mothers with a Child Already Diagnosed with ASD or CFD
If you already have a child with autism spectrum disorder or a confirmed diagnosis of Cerebral Folate Deficiency, testing your FRAA status during a subsequent pregnancy is strongly advisable. This allows your obstetric team and paediatric neurologist to implement proactive monitoring and intervention strategies from the start.
Women with Personal or Family History of Autoimmune Conditions
Autoimmune conditions tend to cluster within families. Women who have personal histories of thyroid autoimmune disease (Hashimoto’s thyroiditis, Graves’ disease), rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, or systemic lupus erythematosus (SLE), or who have close family members with these conditions, are at higher risk of also developing Folate Receptor Autoantibodies.
Women with Unexplained Pregnancy Losses or Poor Obstetric History
Impaired placental folate transport — potentially related to FRAAs — has been proposed as a contributing mechanism in some cases of recurrent pregnancy loss and foetal growth restriction. While the evidence in this specific area is still evolving, women with unexplained recurrent miscarriages or small-for-gestational-age pregnancies may wish to discuss FRAT testing with their maternal-foetal medicine specialist.
Women Who Were Themselves FRAT-Positive Before Pregnancy
If a woman has previously tested FRAT-positive (for example, during investigation of her own neurological or psychiatric symptoms, or as a sibling of a FRAT-positive individual), her obstetrician should be informed so that appropriate folate supplementation strategies can be discussed.
When During Pregnancy Should the FRAT Test Be Done?
Ideally, FRAT testing should be performed either in the pre-conception period (at least 3 months before planned conception) or as early in the first trimester as possible — ideally before week 12. This timing allows:
- Intervention with folinic acid before the most critical period of foetal brain organogenesis
- Sufficient time to adjust supplementation protocols based on results
- Avoidance of the test interference caused by high-dose folic acid supplementation (folate can neutralise FRAAs in the sample, producing false-negative results)
For pre-test preparation, it is important to avoid folic acid supplements and dairy products for 3–4 days before giving the blood sample. Do not stop any prescribed pregnancy supplementation without explicit guidance from your obstetrician or maternal-foetal medicine specialist.
What Happens If the FRAT Test Is Positive During Pregnancy?
A positive result during pregnancy does not mean that harm to your baby has already occurred or is inevitable. It is actionable clinical information that enables targeted intervention. A specialist will typically recommend:
- Transition from standard folic acid to folinic acid (leucovorin) supplementation, under medical supervision
- Elimination of cow’s milk and dairy products from the maternal diet
- Enhanced foetal surveillance and neurodevelopmental monitoring of the baby postnatally
- FRAT testing of the newborn within the first few months of life
- Early enrollment in developmental monitoring programmes and therapy services if indicated
For a comprehensive overview of what a positive FRAT result means and the full range of available interventions, see our guide: FRAT Test Positive? Here’s What It Means and What to Do Next.
FRAT Testing in India: Availability and Accessibility
One of the barriers to wider uptake of FRAT testing during pregnancy in India has historically been limited availability. However, this is changing. Altus Lab Chandigarh now offers FRAT / FOLR1 Antibody testing with free home collection in Chandigarh, Mohali, and Panchkula, and a pan-India courier kit service for expectant mothers across the country.
Our FRAT test service is operated under specialist diagnostic oversight and our reports are accepted at PGIMER Chandigarh, Fortis Mohali, and Max Hospital. You can also explore our FRAT test kit pan-India service for remote collection options.
Frequently Asked Questions
Is the FRAT test safe during pregnancy?
Yes. The FRAT test requires only a simple blood draw — no invasive procedures are involved. It is no different in terms of safety than a routine blood test for haemoglobin or thyroid function.
Will my gynaecologist know about the FRAT test?
Many obstetricians and gynaecologists in India are now becoming aware of FRAT testing, particularly those with an interest in maternal-foetal medicine, neurodevelopmental outcomes, or functional medicine. However, it is still not universally known. You may need to bring the information to your doctor and request a referral to a paediatric neurologist or metabolic specialist for further guidance.
If my FRAT is negative during pregnancy, does that guarantee my child won’t have CFD?
A negative maternal FRAT result significantly reduces the risk of maternally-transmitted FRAA-mediated CFD, but it does not eliminate all risk. CFD can also arise from other mechanisms, including de novo autoantibody production in the child itself. Regular developmental monitoring remains important regardless of maternal FRAT status. For more information on testing children directly, read our guide on FRAT testing for autism and CFD in India.